New Alzheimer’s Blood Tests Are Easy. But Do You Really Want One?

Is the convenience of a simple blood test for Alzheimer's worth the psychological toll of a false positive? A new wave of commercial blood tests promises earlier detection, but many experts warn they may create more anxiety than clarity, especially without a cure.

Forbes contributor Howard Gleckman raises a critical question in his July 2026 article: just because an easy Alzheimer's blood test exists, should you really take it? The tests, which detect biomarkers such as phosphorylated tau 217 (p-tau217), are increasingly available through primary care physicians, making them far simpler and cheaper than amyloid PET scans or lumbar punctures. Yet their sudden ubiquity has outpaced guidance on who should receive them and what the results really mean. Gleckman argues that patients and doctors must carefully weigh the implications before ordering one, especially given the current lack of disease-modifying treatments for many stages of Alzheimer's.

Alzheimer's diagnosis has long been a drawn-out, expensive process. The gold standard involves cognitive exams, brain imaging, and sometimes spinal fluid analysis. The new blood tests cut through that complexity, offering results from a single draw at a fraction of the cost—often under $500 versus thousands for a PET scan. Several companies, including Quest Diagnostics and Labcorp, now offer these tests directly to consumers or through physician orders. The push for early detection aligns with research showing that interventions may be most effective in the preclinical stages of the disease. However, the tests have not been universally validated for asymptomatic individuals, and no consensus exists on how to handle borderline or positive results in people without cognitive symptoms.

According to the article, the core dilemma is whether the benefits of knowing one's biomarker status outweigh the potential harms. For someone already exhibiting memory loss, a positive test can confirm a suspected diagnosis and enable planning. But for a healthy 65-year-old, a positive result may cause years of stress and uncertainty without a clear treatment path. False positive rates, while low—around 5% to 10% depending on the test and cutoff—still mean thousands of people could be wrongly labeled with a devastating disease. Moreover, insurance coverage varies widely, and some tests lack FDA approval, raising concerns about quality control.

Gleckman's analysis ties this to broader trends in consumer genomics and overdiagnosis. Just as direct-to-consumer genetic tests for cancer risk have sparked controversy, Alzheimer's blood tests risk medicalizing normal aging and creating a new class of the 'worried well.' Informed observers, including geriatricians and bioethicists, caution that the tests are being introduced into the market faster than the evidence base supports. They stress that biomarkers are risk factors, not diagnoses—and that lifestyle modifications, while beneficial, remain generic recommendations that do not change based on a blood result.

Looking ahead, the medical community is racing to catch up. The Alzheimer's Association and other groups have convened task forces to develop clinical guidelines. Pending FDA action could set stricter standards for performance and labeling. Meanwhile, patients are advised to have a thorough discussion with their doctor about the purpose of the test, what the results will and will not tell them, and how they plan to act on the information. Until that conversation happens, the easy blood test may be a step forward that many should pause before taking.